Novel Endolysin to Selectively Manage Antimicrobial Resistant S. aureus in Wound Biofilms

该博士研究生的目的是确定抗微生物药物耐药性（AMR）金黄色葡萄球菌对皮肤老化和慢性伤口的贡献，同时测试一种新的针对金黄色葡萄球菌的内毒素技术的选择性和有效性，用于治疗金黄色葡萄球菌皮肤/伤口感染。博士项目将包括对患者样本的分析，以及在威尔金森博士/哈德曼教授和托马斯教授的小组中进行的详细的机械实验。学生还将在Cica生物医学中心进行行业实习，以协助重要的临床前研究。该博士项目涉及与Micreos Pharma合作研究新型内溶素的工作计划（过去2年直接资助40万英镑），以及国家生物膜创新中心（FTMA和POC奖励2021-2022）的先前资助，这些资助为该学生提供了重要的试点数据。赫尔大学和赫尔约克医学院也支持匹配资助的学生，这将与NBIC学生密切相关。

The purpose of this PhD studentship is to determine the contribution of antimicrobial resistant (AMR) S. aureus to skin ageing and chronic wounds, alongside testing the selectivity and efficacy of a novel S. aureus-targeted endolysin technology for the management of AMR S. aureus skin/wound infections. The PhD project will involve analysis of patient samples, alongside detailed mechanistic experiments carried out within the groups of Dr Wilkinson/Prof Hardman and Prof Thomas. The student will also undertake an industry placement with Cica Biomedical to assist with important pre-clinical studies. This PhD project relates to a program of work investigating novel endolysins with Micreos Pharma (£400K direct funding over last 2 years), and previous grants from the National Biofilms Innovation Centre (FTMA and POC awards 2021-2022) that have generated important pilot data for this studentship. A match-funded studentship has also been supported by the University of Hull and Hull York Medical School, which will closely align to the NBIC studentship.